MX2019005693A - Factor viii direccionado a los globulos rojos y metodo para su uso. - Google Patents
Factor viii direccionado a los globulos rojos y metodo para su uso.Info
- Publication number
- MX2019005693A MX2019005693A MX2019005693A MX2019005693A MX2019005693A MX 2019005693 A MX2019005693 A MX 2019005693A MX 2019005693 A MX2019005693 A MX 2019005693A MX 2019005693 A MX2019005693 A MX 2019005693A MX 2019005693 A MX2019005693 A MX 2019005693A
- Authority
- MX
- Mexico
- Prior art keywords
- factor viii
- red blood
- blood cell
- same
- cell targeted
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 3
- 210000003743 erythrocyte Anatomy 0.000 title abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 2
- 102000001690 Factor VIII Human genes 0.000 abstract 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Moléculas direccionadas del factor VIII que comprenden un factor VIII unido a al menos un dominio que se une específicamente a una proteína de la membrana de los glóbulos rojos. Los factores de coagulación direccionados descriptos tienen una acción con una duración prolongada, por lo que son más eficaces para tratar enfermedades hematológicas como la hemofilia A.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662422600P | 2016-11-16 | 2016-11-16 | |
PCT/US2017/061509 WO2018093766A1 (en) | 2016-11-16 | 2017-11-14 | Red blood cell targeted factor viii and method of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019005693A true MX2019005693A (es) | 2019-08-14 |
Family
ID=60484499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005693A MX2019005693A (es) | 2016-11-16 | 2017-11-14 | Factor viii direccionado a los globulos rojos y metodo para su uso. |
Country Status (15)
Country | Link |
---|---|
US (2) | US11104718B2 (es) |
EP (1) | EP3541834A1 (es) |
JP (1) | JP2020504084A (es) |
KR (1) | KR20190083355A (es) |
CN (1) | CN110177804A (es) |
AR (1) | AR110079A1 (es) |
AU (1) | AU2017360979A1 (es) |
BR (1) | BR112019010034A2 (es) |
CA (1) | CA3043702A1 (es) |
IL (1) | IL266609A (es) |
MX (1) | MX2019005693A (es) |
PE (1) | PE20190966A1 (es) |
RU (1) | RU2019118427A (es) |
TW (1) | TW201831508A (es) |
WO (1) | WO2018093766A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110177804A (zh) * | 2016-11-16 | 2019-08-27 | 拜尔健康护理有限责任公司 | 红细胞靶向的因子viii及使用其的方法 |
WO2019215590A1 (en) * | 2018-05-07 | 2019-11-14 | Anokion Sa | Glycophorin a antigen-binding proteins |
EP4051703A1 (en) * | 2019-11-01 | 2022-09-07 | Freeline Therapeutics Limited | Factor viii polypeptide |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752582A (en) * | 1982-12-17 | 1988-06-21 | The United States Of America As Represented By The United States Department Of Energy | Monoclonal antibodies to human glycophorin A and cell lines for the production thereof |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1994009034A1 (en) | 1992-10-12 | 1994-04-28 | Agen Limited | Clot directed anticoagulant, process for making same and methods of use |
MXPA04010851A (es) * | 2002-05-01 | 2005-02-14 | Schering Ag | Proteinas de fusion de trombomodulina dirigidas al factor tisular novedoso como anticoagulantes. |
NO20210454A1 (no) | 2004-11-12 | 2007-06-27 | Bayer Healthcare Llc | Setedirigert modifikasjon av FVIII |
US8333973B2 (en) * | 2008-01-02 | 2012-12-18 | The Trustees Of The University Of Pennsylvania | Targeting recombinant therapeutics to circulating red blood cells |
AU2009219232B2 (en) * | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
KR101841870B1 (ko) * | 2008-05-16 | 2018-03-23 | 바이엘 헬스케어 엘엘씨 | 표적화 응고 인자 및 그의 사용 방법 |
JP6017422B2 (ja) * | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合療法 |
US9517257B2 (en) * | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
BR112013021661A2 (pt) | 2011-03-02 | 2016-11-22 | Novo Nordisk As | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas |
CN110177804A (zh) * | 2016-11-16 | 2019-08-27 | 拜尔健康护理有限责任公司 | 红细胞靶向的因子viii及使用其的方法 |
-
2017
- 2017-11-14 CN CN201780083669.3A patent/CN110177804A/zh active Pending
- 2017-11-14 PE PE2019001005A patent/PE20190966A1/es unknown
- 2017-11-14 MX MX2019005693A patent/MX2019005693A/es unknown
- 2017-11-14 BR BR112019010034A patent/BR112019010034A2/pt not_active Application Discontinuation
- 2017-11-14 US US16/349,794 patent/US11104718B2/en active Active
- 2017-11-14 AU AU2017360979A patent/AU2017360979A1/en not_active Abandoned
- 2017-11-14 WO PCT/US2017/061509 patent/WO2018093766A1/en unknown
- 2017-11-14 AR ARP170103170A patent/AR110079A1/es unknown
- 2017-11-14 KR KR1020197016809A patent/KR20190083355A/ko unknown
- 2017-11-14 RU RU2019118427A patent/RU2019118427A/ru not_active Application Discontinuation
- 2017-11-14 TW TW106139258A patent/TW201831508A/zh unknown
- 2017-11-14 EP EP17805367.4A patent/EP3541834A1/en active Pending
- 2017-11-14 CA CA3043702A patent/CA3043702A1/en not_active Abandoned
- 2017-11-14 JP JP2019525863A patent/JP2020504084A/ja active Pending
-
2019
- 2019-05-14 IL IL266609A patent/IL266609A/en unknown
-
2021
- 2021-06-18 US US17/351,527 patent/US20220089685A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2019118427A (ru) | 2020-12-17 |
BR112019010034A2 (pt) | 2019-09-03 |
WO2018093766A1 (en) | 2018-05-24 |
CA3043702A1 (en) | 2018-05-24 |
US20220089685A1 (en) | 2022-03-24 |
JP2020504084A (ja) | 2020-02-06 |
US20190359687A1 (en) | 2019-11-28 |
AU2017360979A1 (en) | 2019-05-30 |
EP3541834A1 (en) | 2019-09-25 |
PE20190966A1 (es) | 2019-07-08 |
US11104718B2 (en) | 2021-08-31 |
CN110177804A (zh) | 2019-08-27 |
KR20190083355A (ko) | 2019-07-11 |
AR110079A1 (es) | 2019-02-20 |
IL266609A (en) | 2019-07-31 |
TW201831508A (zh) | 2018-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001897A1 (es) | Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509) | |
CL2015003731A1 (es) | Inhibidores de bromodominios | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
MX2017007148A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. | |
EA201792441A2 (ru) | Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
EA201690969A1 (ru) | Способы и композиции для лечения связанных со старением состояний | |
BR112016000654A2 (pt) | composições para a modulação de expressão de tau | |
EA201591430A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
EA201591426A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201690898A1 (ru) | Способы лечения таупатии | |
EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201591432A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
MX2018010508A (es) | Preparaciones mejoradas de celulas progenitoras hepaticas adultas. | |
MX2023010076A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
CL2015003174A1 (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
EP3265477A4 (en) | DOUBLE SIGNALING PROTEIN (DSP) FUSION PROTEINS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DISEASES |